Change in Nutritional Status during Hospitalization and Prognosis in Patients with Heart Failure with Preserved Ejection Fraction

Akihiro Sunaga 1, Shungo Hikoso 1,*, Takahisa Yamada 2, Yoshio Yasumura 3, Shunsuke Tamaki 4, Masamichi Yano 5, Takaharu Hayashi 6, Yusuke Nakagawa 7, Akiti Nakagawa 3, Masahiro Seo 2, Hiroyuki Kurakami 9, Tomomi Yamada 9, Tetsuhiha Kitamura 10, Taiki Sato 1, Bolrathanak Oeun 1, Hirota Kida 1, Yohei Sotomi 1, Tomoharu Dohi 1, Katsuki Okada 1, Hiroya Mizuno 1, Daisaku Nakatani 1, Yasushi Sakata 1 and on behalf of the OCVC-Heart Failure Investigators †

1 Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan
2 Division of Cardiology, Osaka General Medical Center, 3-1-56 Mandraigashhi, Sumiyoshi-ku, Osaka 558-8558, Japan
3 Division of Cardiology, Amagasaki Chuo Hospital, 1-12-1 Shioe, Amagasaki 661-0976, Japan
4 Department of Cardiology, Rinku General Medical Center, 2-23 Ouraikita, Rinku, Izumisano 598-8577, Japan
5 Division of Cardiology, Osaka Rosai Hospital, 1179-3 Nagasonoecho, Kitaku, Sakai 591-8025, Japan
6 Cardiovascular Division, Osaka Police Hospital, 10-31 Kitayamachoo, Tennojiku, Osaka 543-0035, Japan
7 Division of Cardiology, Kawanishi City Hospital, 5-21-1, Kawanishi 666-0195, Japan
8 Department of Medical Informatics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan
9 Department of Medical Innovation, Osaka University Hospital, 2-15 Yamadaoka, Suita 565-0871, Japan
10 Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Japan
* Correspondence: hikoso@cardiology.med.osaka-u.ac.jp; Tel.: +81-66-793-632; Fax: +81-6-6879-3299
† Investigators of the OCVC-Heart Failure are indicated in the Acknowledgments.

Abstract: The impact of changes in nutritional status during hospitalization on prognosis in patients with heart failure with preserved ejection fraction (HFpEF) remains unknown. We examined the association between changes in the Geriatric Nutritional Risk Index (GNRI) and prognosis during hospitalization in patients with HFpEF stratified by nutritional status on admission. Nutritional status did and did not worsen in 348 and 349 of 697 patients with high GNRI on admission, and in 142 and 143 of 285 patients with low GNRI on admission, respectively. Kaplan–Meier analysis revealed no difference in risk of the composite endpoint, all-cause death, or heart failure admission between patients with high GNRI on admission whose nutritional status did and did not worsen. In contrast, patients with low GNRI on admission whose nutritional status did not worsen had a significantly lower risk of the composite endpoint and all-cause death than those who did. Multivariable analysis revealed that worsening nutritional status was independently associated with a higher risk of the composite endpoint and all-cause mortality in patients with low GNRI on admission. Changes in nutritional status during hospitalization were thus associated with prognosis in patients with malnutrition on admission, but not in patients without malnutrition among those with HFpEF.

Keywords: heart failure with preserved ejection fraction; nutritional status; GNRI; malnutrition

1. Introduction

Malnutrition is common in patients with heart failure and is associated with poor prognosis [1,2], making assessment and management of nutritional status important for the treatment of heart failure. A number of nutritional assessment tools have been developed [3–6]. Among them, the Geriatric Nutritional Risk Index (GNRI), which is calculated based on albumin and body mass index [4], is commonly used to assess nutritional status in
patients with heart failure [7–9]. GNRI is supposed to be the most appropriate nutritional assessment tool for patients with heart failure, since GNRI is thought to be less affected by a change of volume which accompanies heart failure treatment [10] and has the best prognostic value among several nutritional assessment tools [2].

Pathophysiology of heart failure with preserved ejection fraction (HFP EF) is heterogeneous. Malnutrition has been thought to be one of the causes of HFP EF [11] as well as a prognostic factor. Nutritional status at admission or discharge assessed by GNRI is reportedly associated with prognosis in patients with HFP EF [10,12]. Hospitalized elderly patients are at high risk of malnutrition and are more likely to be worse off after admission than when they were admitted [13]. Elderly patients are more likely to have HFP EF [14]. However, the impact of changes in nutritional status during hospitalization on prognosis in patients with HFP EF remains unknown. While it is important to examine the relationship between changes in nutritional status and prognosis to assess whether interventions in nutritional status can improve prognosis, it should be noted that baseline nutritional status itself has a strong prognostic impact. Therefore, the effect of changes in nutritional status may differ according to patients’ nutritional status at admission.

The purpose of this study is to determine the association between changes in GNRI and prognosis during hospitalization in patients with HFP EF stratified by nutritional status on admission.

2. Materials and Methods

2.1. Study Patients

Of the 1095 patients registered in the prospective, multicenter, observational study of patients with HFP EF (PURSUIT-HFP EF) registry [15] between June 2016 and January 2021, 86 patients without GNRI, 12 patients with in-hospital death, and 15 patients with amyloidosis, chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension were excluded. A total of 982 patients were studied. The registry, which started in June 2016, enrolled patients hospitalized with a diagnosis of decompensated heart failure based on the Framingham criteria and who met the following criteria: left ventricular ejection fraction (LVEF) ≥ 50% on a transthoracic cardiac echocardiographic (TTE) test on admission and N-terminal pro-brain natriuretic peptide (NT-proBNP) ≥ 400 pg/mL or brain natriuretic peptide ≥ 100 pg/mL on admission. We excluded patients with severe aortic stenosis, aortic regurgitation, mitral stenosis, or mitral regurgitation due to structural changes in the valve detected by TTE on admission. We also excluded patients under 20 years old, patients with acute coronary syndrome on admission, patients with poor life prognoses within six months due to non-cardiac diseases, patients who had received a heart transplant, and patients considered not to be appropriate for the study by the attending physician. Thirty-one facilities participated in this study. We did not have any protocol for nutritional treatment after discharge.

All patients provided written informed consent for participation in this study, which was approved by the ethics committee of each participating hospital. This study followed the ethical guidelines outlined by the Helsinki Declaration. The study protocol was approved by the Institutional Review Board of all participating facilities.

2.2. Data Collection

We collected data such as detailed past history, accompanying diseases, quality of life, Clinical Frailty Scale [16], medication history, and laboratory and echocardiographic data. Each patient was followed to collect outcome data such as mortality, cause of death, number of hospitalizations, and cause of hospitalization.

Change in sodium level was calculated as sodium at discharge—sodium on admission. Change in hemoglobin level was calculated as hemoglobin level at discharge—hemoglobin level on admission.

In echocardiography, inferior vena cava diameter was measured using a standard method. LVEF was measured using the Simpson method. Left ventricular mass index
(LVMI) was calculated using the left ventricular diastolic diameter, left ventricular posterior thickness, interventricular septum thickness, and body surface area. E/e’ was the mean of septal E/e’ and lateral E/e’. The tricuspid pressure gradient was determined using the simplified Bernoulli equation.

Plasma volume was calculated using Hakim formula as follows: (1 − hematocrit) × [a + (b × body weight)] (a = 1530 in males and a = 864 in females, b = 41.0 in males and b = 47.9 in females) [17]. Change in plasma volume was calculated by plasma volume at discharge–plasma volume on admission.

Prognostic nutrition index (PNI) [1] and controlling nutritional status (CONUT) [5] score were calculated on admission and at discharge. Change in PNI was calculated as PNI at discharge–PNI on admission. Change in CONUT score was calculated as CONUT score at discharge–CONUT score on admission.

Research cardiologists and specialized research nurses recorded the patients’ data during their hospital stay. In-hospital data were transferred to the data collection center for processing and analysis. Medical history was obtained on admission. Vital signs, body mass index (BMI), echocardiography, laboratory data, and medication use were obtained both on admission and at discharge.

2.3. GNRI

GNRI was calculated as follows: 14.89 × albumin (g/dL) + 41.7 × BMI (kg/m²)/22. GNRI was calculated both on admission and at discharge. Delta GNRI was calculated as GNRI at discharge–GNRI on admission. GNRI was classified based on the risk of malnutrition as none (>98), mild (92 to 98), moderate (82 to <92), or severe (<82) [4]. First, we divided the participants into two groups based on whether their GNRI was high (≥92) or low (<92). Each group was then further dichotomized into high and low according to the median delta GNRI (Figure 1).

![Figure 1](image-url)
2.4. Statistical Analysis

Continuous variables are expressed as median (interquartile range). Categorical data are presented as percentages unless otherwise specified. Tests for significance were conducted using the unpaired t-test, Mann–Whitney U test or Wilcoxon signed-rank test for continuous variables, and the chi-squared test or Fisher’s exact test for categorical variables. The primary endpoint of this study was the composite of all-cause mortality and heart failure admission for 2 years. Secondary endpoints were all-cause mortality and heart failure admission for 2 years. Endpoints were estimated using Kaplan–Meier curves and statistical differences were determined using the log-rank test. Univariable analysis and multivariable analysis using a Cox proportional hazards regression model were also performed. The multivariable analysis was adjusted for age, sex, history of heart failure hospitalization, hypertension, diabetes, hemoglobin, estimated glomerular filtration rate, N-terminal pro-brain natriuretic peptide level, and use of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. These covariates are well-established predictors of risk in patients with HFpEF [18,19]. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for each endpoint using Cox proportional hazards regression models. All statistical analyses were performed using SPSS version 25 (IBM Corp., Armonk, NY, USA). Statistical significance was defined as p < 0.05.

3. Results

3.1. Baseline Characteristics

The median follow-up period was 421 [260, 730] days. Of the 982 patients, 697 had high and 285 had low GNRI on admission. The baseline characteristics and prognosis of these groups are shown in Supplementary Table S1 and Figure S1. As mentioned in the Introduction section, we hypothesized that those whose nutritional status worsened during hospitalization may have a worse prognosis than would be expected based on their nutritional status at admission, whereas those whose nutritional status did not worsen may have a better prognosis.

To determine the association between changes in GNRI during hospitalization and prognosis in patients with HFpEF stratified by nutritional status on admission, we divided the patients into two groups: those with high GNRI on admission and those with low GNRI on admission. The distribution of the patients’ delta GNRI stratified by high or low GNRI on admission is shown in Figure 2. The median delta GNRI in patients with high GNRI on admission was −7.1 and that in patients with low GNRI on admission was −3.6. We further divided the 697 patients with high GNRI on admission into those whose nutritional status worsened (delta GNRI < −7.1) and those that did not (delta GNRI ≥ −7.1), and 285 patients with low GNRI on admission into the same categories (delta GNRI < −3.6 vs. delta GNRI ≥ −3.6).

The baseline characteristics of these four groups are shown in Table 1. Patients with high GNRI and low GNRI on admission whose nutritional status worsened had significantly lower hemoglobin and albumin. Among patients with high GNRI on admission, patients with worsening nutritional status showed older age, higher frequency of NYHA ≥II and use of calcium channel blocker, higher LVMI, sodium level and NT-proBNP level, and lower hemoglobin and albumin level. Among patients with low GNRI on admission, patients with worsening nutritional status showed older age, lower BMI, lower frequency of diabetes mellitus, use of aldosterone antagonist, higher sodium level, and lower hemoglobin and albumin levels. The comparison of GNRI, albumin, and BMI on admission and at discharge among the four groups is shown in Figure 3. While albumin levels at discharge were higher than that on admission in patients with high and low GNRI on admission whose nutritional status did not worsen, they were lower in both patients with high and low GNRI on admission whose nutritional status worsened. BMI at discharge was lower than that on admission in all groups.
Figure 2. Distribution of delta GNRI stratified by low or high GNRI on admission. The median delta GNRI value in patients with low GNRI on admission was −3.6 (A) and that in patients with high GNRI on admission was −7.1 (B). GNRI, geriatric nutritional risk index.

Table 1. Baseline characteristics.

| Variable | High GNRI on Admission | Low GNRI on Admission | p  | With Worsening Nutritional Status | Without Worsening Nutritional Status | p  | With Worsening Nutritional Status | Without Worsening Nutritional Status | p  |
|----------|-------------------------|-----------------------|----|---------------------------------|-------------------------------------|----|---------------------------------|-------------------------------------|----|
| Age, years | 83 (78, 87) | 81 (75, 86) | 0.001 | 85 (78, 90) | 83 (78, 88) | 0.043 |
| Male, n (%) | 162 (46.6) | 174 (49.9) | 0.383 | 49 (34.5) | 62 (43.4) | 0.126 |
| Body mass index, kg/m² | 22.8 (20.5, 25.4) | 23.1 (21.2, 25.4) | 0.214 | 17.8 (16.6, 19.3) | 18.5 (16.9, 20.3) | 0.016 |
| Current smoking, n (%) | 31 (9.1) | 39 (11.2) | 0.625 | 12 (8.6) | 19 (13.4) | 0.323 |
| NYHA ≥ 2, n (%) | 222 (64.3) | 237 (67.8) | 0.008 | 103 (74.1) | 103 (73.6) | 0.920 |
| Systolic blood pressure, mmHg | 120 (106, 132) | 118 (108, 130) | 0.715 | 118 (105, 134) | 118 (103, 139) | 0.623 |
| Heart rate, bpm | 120 (106, 132) | 118 (108, 130) | 0.715 | 118 (105, 134) | 118 (103, 139) | 0.623 |
| Prior heart failure admission, % | 312 (90.2) | 302 (86.5) | 0.128 | 108 (76.6) | 110 (76.9) | 0.049 |
| Hypertension, n (%) | 314 (90.2) | 302 (86.5) | 0.128 | 108 (76.6) | 110 (76.9) | 0.049 |
| Diabetes mellitus, n (%) | 126 (36.4) | 134 (38.5) | 0.303 | 46 (32.6) | 40 (28.4) | 0.438 |
| Dyslipidemia, n (%) | 156 (45.1) | 170 (49.0) | 0.303 | 46 (32.6) | 40 (28.4) | 0.438 |
| Stroke, n (%) | 136 (39.3) | 143 (40.9) | 0.303 | 46 (32.6) | 40 (28.4) | 0.438 |
| Atrial fibrillation, n (%) | 165 (47.4) | 172 (49.3) | 0.303 | 46 (32.6) | 40 (28.4) | 0.438 |
| Chronic kidney disease, n (%) | 146 (42.2) | 150 (43.8) | 0.303 | 46 (32.6) | 40 (28.4) | 0.438 |
| Malignant disease, n (%) | 156 (45.1) | 170 (49.0) | 0.303 | 46 (32.6) | 40 (28.4) | 0.438 |
| LVEF, % | 61 (56, 65) | 61 (56, 65) | 0.761 | 61 (56, 66) | 60 (56, 66) | 0.655 |
| Left atrial diameter, mm | 45 (40, 50) | 46 (40, 51) | 0.128 | 45 (40, 51) | 46 (40, 51) | 0.045 |
| LVMI, g/m² | 107 (92, 122) | 102 (85, 125) | 0.013 | 100 (85, 119) | 100 (83, 119) | 0.118 |
| Mean E/e' | 13 (10, 17) | 13 (10, 17) | 0.641 | 13 (10, 17) | 13 (10, 17) | 0.641 |
| TRPG, mmHg | 27 (22, 32) | 27 (22, 32) | 0.768 | 27 (22, 32) | 27 (22, 32) | 0.768 |
| Hemoglobin, g/dL | 11.1 (9.7, 12.5) | 12.0 (10.8, 13.5) | <0.001 | 10.5 (9.2, 11.7) | 11.1 (10.1, 12.3) | <0.001 |
| Hemoglobin, g/dL | 11.1 (9.7, 12.5) | 12.0 (10.8, 13.5) | <0.001 | 10.5 (9.2, 11.7) | 11.1 (10.1, 12.3) | <0.001 |
| Creatinine, mg/dL | 40.3 (29.0, 54.4) | 41.5 (31.6, 53.8) | 0.428 | 42.6 (32.6, 58.4) | 44.8 (32.6, 57.0) | 0.903 |
| eGFR, ml/min/1.73 m² | 13 (10, 17) | 13 (10, 17) | 0.641 | 13 (10, 17) | 13 (10, 17) | 0.641 |
| Albumin, g/dL | 3.3 (3.1, 3.6) | 3.3 (3.1, 3.6) | <0.001 | 3.0 (2.6, 3.1) | 3.3 (3.1, 3.6) | <0.001 |
| NT-proBNP, pg/mL | 1100 (886, 2375) | 803 (375, 1979) | <0.001 | 1350 (562, 3080) | 1399 (506, 2607) | 0.948 |
| ACE-I or ARB, n (%) | 211 (60.6) | 193 (55.3) | 0.154 | 58 (40.8) | 73 (51.0) | 0.084 |
| Calcium channel blocker, n (%) | 192 (55.3) | 162 (46.4) | 0.154 | 58 (40.8) | 73 (51.0) | 0.084 |
| Beta blocker, n (%) | 199 (57.3) | 194 (55.6) | 0.154 | 58 (40.8) | 73 (51.0) | 0.084 |
| Diuretics, n (%) | 283 (81.3) | 294 (84.2) | 0.154 | 58 (40.8) | 73 (51.0) | 0.084 |
| Aldosterone antagonist, n (%) | 130 (37.4) | 130 (37.4) | 0.028 | 48 (33.8) | 66 (46.2) | 0.033 |
| Statin, n (%) | 122 (35.2) | 132 (37.8) | 0.465 | 34 (23.9) | 46 (32.2) | 0.122 |
| Hospital stay, days | 17 (13, 23) | 17 (13, 23) | 0.003 | 19 (13, 27) | 17 (12, 26) | 0.313 |
| Quality of life score | 0.776 (0.587, 0.895) | 0.825 (0.667, 1.000) | 0.001 | 0.709 (0.491, 0.869) | 0.732 (0.504, 0.875) | 0.805 |

Table 1. Baseline characteristics.

GNRI, geriatric nutritional risk index; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; TRPG, tricuspid regurgitation pressure gradient; IVC, inferior vena cava; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

Change in patients’ condition during admission was shown in Supplementary Table S2. The change in plasma volume between admission and discharge was not significantly different between patients with and without worsening nutritional status among both patients with high and low GNRI on admission. In patients with high GNRI on admission, there was no significant difference in the change in serum sodium between patients with worsening nutritional status and those without. In patients with low GNRI on admis-
patients with worsening nutritional status had a greater decrease in serum sodium than those without. Patients with worsening nutritional status had a greater decrease in hemoglobin levels than those without among both patients with high and low GNRI on admission. Patients with worsening nutritional status had a greater decrease in PNI and a greater increase in CONUT score than those without worsening nutritional status among both patients with high and low GNRI on admission. (Supplementary Table S2).

Figure 3. Change in GNRI, albumin and BMI during hospitalization. The blue bar shows the value on admission and the green bar shows that at discharge. (A–C) show the values of patients with low GNRI on admission, and (D–F) show the values of patients with high GNRI on admission. Asterisk indicates the value under 1st quartile $-$ 3 × inter quartile range and the value over 3rd quartile + 3 × inter quartile range.

3.2. Outcomes

Kaplan–Meier analysis showed that patients with low GNRI on admission had a higher risk of the composite endpoint and all-cause mortality, but a similar risk of heart failure hospitalization to those with high GNRI on admission (Supplementary Figure S1). In patients with high GNRI on admission, Kaplan–Meier analysis at follow-up of 2 years revealed no significant difference in risk of the composite endpoint, all-cause death, or heart failure admission between patients whose nutritional status did and did not worsen. In patients with low GNRI on admission, Kaplan–Meier analysis at follow-up of 2 years revealed that those whose nutritional status worsened had a significantly higher risk of the composite endpoint and all-cause death than those who did not (Figure 4).

In patients with high GNRI on admission, Kaplan–Meier analysis until 6 months after discharge revealed no significant difference in risk of the composite endpoint (log-rank $p = 0.425$), all-cause death (log-rank $p = 0.995$), or heart failure admission (log-rank $p = 0.400$) between patients whose nutritional status did and did not worsen. In patients with low GNRI on admission, Kaplan–Meier analysis at follow-up of 6 months revealed that those whose nutritional status worsened tended to have a higher risk of the composite endpoint (log-rank $p = 0.056$) (Supplementary Figure S2).
Figure 4. Comparison of outcomes between patients whose nutritional status did and did not worsen stratified by high or low GNRI on admission. (A–C) show the survival curves of patients with high GNRI on admission, and (D–F) show the survival curves of patients with low GNRI on admission. GNRI, geriatric nutritional risk index.

The incidence rates of all-cause death, cardiac death and non-cardiac death, and heart failure admission in the four groups are shown in Table 2. All-cause death, cardiac death and non-cardiac death, and heart failure admission occurred more frequently in patients with low GNRI on admission and whose nutritional status worsened compared to the other groups but were comparable to those with high GNRI on admission.

Table 2. Incident rate of endpoint.

|                      | High GNRI on Admission |                        | Low GNRI on Admission |                      |
|----------------------|------------------------|------------------------|-----------------------|---------------------|
|                      | With Worsening         | Without Worsening      | With Worsening        | Without Worsening   |
|                      | Nutritional Status     | Nutritional Status     | Nutritional Status    | Nutritional Status  |
|                      | Number of Events       | Person-Years IR        | Number of Events      | Person-Years IR     |
| Composite endpoint   | 104                    | 365.5                  | 91                    | 366.6               |
| All-cause death      | 38                     | 435.7                  | 24                    | 445.8               |
| HF admission         | 84                     | 365.5                  | 80                    | 366.6               |
| GNRI, geriatric nutritional risk index; IR, incident rate; HF, heart failure.

Results of the multivariable analysis with a Cox proportional hazard model of the composite endpoint, all-cause mortality, and heart failure admission are shown in Table 3. Worse nutritional status was independently associated with a higher risk of the composite endpoint and all-cause mortality in patients with low GNRI on admission, but not in patients with high GNRI on admission.
Table 3. Hazard ratio of no worsening nutritional status for each endpoint.

|                      | Unadjusted HR (95% CI) | p      | Adjusted HR (95% CI) | p      |
|----------------------|------------------------|--------|----------------------|--------|
| High GNRI on admission |                        |        |                      |        |
| Composite endpoint    | 1.15 (0.87–1.52)       | 0.337  | 1.01 (0.73–1.39)     | 0.974  |
| All-cause death       | 1.60 (0.97–2.65)       | 0.065  | 1.69 (0.92–3.04)     | 0.094  |
| Heart failure admission | 1.07 (0.79–1.45)     | 0.668  | 0.92 (0.63–1.30)     | 0.629  |
| Low GNRI on admission |                        |        |                      |        |
| Composite endpoint    | 1.79 (1.21–2.65)       | 0.004  | 1.65 (1.05–2.59)     | 0.030  |
| All-cause death       | 2.10 (1.25–3.54)       | 0.004  | 1.84 (1.04–3.26)     | 0.038  |
| Heart failure admission | 1.36 (0.81–2.30)     | 0.243  | 1.37 (0.75–2.49)     | 0.309  |

Adjusted for age, sex, history of heart failure hospitalization, hypertension, diabetes, hemoglobin, eGFR, NT-proBNP, ACE-I/ARB, HR, hazard ratio; CI, confidence interval; GNRI, geriatric nutritional risk index, eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

4. Discussion

4.1. Main Findings

We showed that severe worsening nutritional status during treatment for decompen-sated heart failure was significantly associated with worse prognosis in patients with low GNRI on admission, but not in patients with high GNRI on admission among those with HFpEF. This study is the first to report the impact of changes in nutritional status on prognosis in patients with HFpEF. Our findings may suggest the importance of avoiding worsening nutritional status for preventing poor prognosis, especially in patients with malnutrition.

4.2. Previous Studies

We clarified that the progression of malnutrition has prognostic impacts in patients with malnutrition at baseline in patients with HFpEF. A number of previous studies have reported the role of malnutrition in patients with heart failure including HFpEF. Minamisawa et al. reported that patients with HFpEF are at an elevated risk for malnutrition, which was associated with an increased risk for CV events in 1677 patients enrolled in the American regions of the TOPCAT trial [9]. Chien et al. examined 1120 patients and reported that malnutrition was frequently and strongly associated with systemic inflammation in Asian patients hospitalized for acute HFpEF [20]. Hirose et al. examined 201 patients with HFrEF and 250 patients with HFpEF and reported that among patients with acute decompensated HF, assessment of nutritional status with GNRI is useful for stratifying patients at high risk for longer length of hospital stay in HFpEF but not in HFrEF [21]. Watanabe et al. analyzed 420 patients and reported that inflammation was associated with malnutrition in HFmrEF and HFpEF, while congestion was an independent predictor of malnutrition in HFrEF [22]. Nishi et al. examined 110 patients and reported that nutritional screening using the GNRI at discharge is helpful to predict the long-term prognosis of elderly HFpEF patients [12]. All these previous reports examined the association between malnutrition and heart failure including HFpEF at a one-time point. However, there have been no reports about the association between change in nutrition status during hospitalization and prognosis in patients with HFpEF.

4.3. Cardiac Cachexia and Malnutrition

In this study, nearly 30% of patients showed malnutrition on admission, and a consider-able number of patients showed worsening nutrition during hospitalization. In heart failure patients, cardiac cachexia is common. Increases in catecholamines, inflammatory cytokines, and insulin resistance result in protein catabolism, lipolysis, and bone loss [23,24]. Cardiac cachexia and malnutrition are closely related. In particular, acute heart failure increases the risk of malnutrition due to decreased albumin production due to hepatic congestion, decreased absorption of nutrients due to intestinal edema, and decreased food intake. All of these factors lead to hypermetabolism, impaired feeding and absorption, and
finally malnutrition [25–27]. Heart failure leads to malnutrition, and malnutrition further exacerbates heart failure. Since patients with heart failure are likely to be malnourished [1,2], their nutritional status should be monitored during heart failure treatment.

4.4. Assessment of Nutritional Status during Hospitalization

We used the GNRI to assess nutritional status in this study. While several other tools such as the Malnutrition Universal Screening Tool, Subjective Global Assessment, and Nutritional Risk Screening 2002 [28] have also been used to assess nutritional status, the results of these measures may be influenced by the experience of the examiner because they involve subjective assessments. Further, CONUT [5] and PNI [1], two simple and objective measures that include lymphocyte counts may be unsuitable for examining nutritional status in the acute phase, since the infection was frequently accompanied in patients with acute decompensated heart failure.

In contrast, GNRI may be the most appropriate for assessing changes in nutritional status during hospitalization, because it is less affected by heart failure treatment. Since volume reduction results in a decrease in BMI and an increase in albumin, the effects of volume reduction may be minimized in changes in GNRI, and we expect that changes in GNRI mainly reflect nutritional status in our study. Actually, our data indicated that a decrease in plasma volume has tended to be less in patients with worsening nutritional status than in those without nutritional status in both groups (Supplementary Table S2), suggesting that change in GNRI does not correlate with the change in volume. Moreover, change in hemoglobin level, PNI, and CONUT score had decreased more in patients with worsening nutritional status than those without nutritional status in both groups (Supplementary Table S2). All these findings suggest that the change in GNRI in this study reflected the true occurrence of new malnutrition rather than a measurement bias due to volume reduction with heart failure treatment, whereas we cannot rule out the possibility that volume reduction may affect these changes to some extent.

4.5. Relationship between Change in Nutritional Status and Prognosis

Our data suggest that a worsening nutritional status during hospitalization had a negative impact on long-term prognosis in patients with low GNRI on admission, but not in those with high GNRI on admission. Since malnutrition on admission is reportedly associated with poor prognosis in patients with heart failure [10], assessment of nutritional status on admission is important for risk stratification and should be routinely performed. The usefulness of risk assessment based on nutrition has also been reported in outpatients [9]. Our data further emphasize the importance of continuous monitoring and effort to avoid worsening nutritional status during treatment for decompensated heart failure. On the other hand, the association between the change in nutritional status and the shorter-term prognosis was less significant. This may be due to a lack of statistical power resulting from the smaller number of events. Another possibility is that a change of GNRI during hospitalization may have more impact on the long-term prognosis than the short-term prognosis.

It is interesting that the impact of a deterioration in nutritional status differed according to baseline nutritional status. This may be due to a difference in reserve capacity for nutritional conditions between patients with and without malnutrition. Malnutrition can cause hypoproteinemia and weakened immunity, leading to exacerbation of heart failure and infections [29]. Conversely, worsening heart failure causes a deterioration of patients’ nutritional status due to intestinal edema and reduced food intake, creating a vicious cycle [24,25,30]. Patients with malnutrition on admission can more easily enter this vicious cycle than those without malnutrition, which may explain the poor prognosis in only malnourished patients. Careful monitoring and management of nutritional status are especially important in these populations.

Our data may also imply that maintaining or improving nutritional status can improve prognosis in patients with malnutrition on admission. Nutritional support has been
reported to improve nutritional status in a meta-analysis [31]. Nutritional therapy was associated with lower mortality rates than conventional treatment in a population in which about 25% of patients had heart failure [32]. Nutritional interventions have been reported to improve LVEF and decrease NT-proBNP by adjusting inflammatory levels [33]. Our current study is in line with these previous reports, and these findings suggest that nutritional interventions during hospitalization that do not worsen nutritional status may improve prognosis in patients with HFP EF. Further prospective studies are needed to examine the effect of nutritional intervention on prognosis. Regarding nutritional strategies to intervene against malnutrition, the use of individualized nutritional support to reach protein and caloric goals during the hospital stay improved important clinical outcomes, including survival, compared with standard hospital food in medical inpatients at nutritional risk [34]. A previous study reported that nutritional support alone may be insufficient as an intervention and that nutritional support in combination with exercise therapy may be more effective [35]. Appropriate interventions for these populations should be also investigated.

4.6. Limitations

We only used the GNRI to assess nutritional status. Additional studies using other nutritional indicators might be useful to confirm our findings. Further studies are also needed to determine whether nutritional interventions improve prognosis.

5. Conclusions

Worsening nutritional status during hospitalization was associated with prognosis in patients with low GNRI on admission, but not in patients with high GNRI on admission among those with HFP EF. Nutritional assessment by GNRI on admission to identify patients with malnutrition, and interventions on nutritional status in these populations may be useful for improving prognosis in patients with HFP EF.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14204345/s1, Figure S1: Comparison of outcomes between patients with high or low GNRI on admission.; Figure S2: Comparison of outcomes until 6 months after discharge between patients whose nutritional status did and did not worsen stratified by high or low GNRI on admission; Table S1: Baseline characteristics grouped by GNRI; Table S2: Change in patients’ condition during admission.

Author Contributions: Conceptualization, A.S.; Data curation, A.S., S.H., T.S. and Y.S. (Yohei Sotomi); Formal analysis, A.S., H.K. (Hiroyuki Kurakami) and T.Y. (Tomomi Yamada); Funding acquisition, S.H. and Y.S. (Yasushi Sakata); Investigation, A.S.; Methodology, A.S.; Project administration, S.H. and Y.S. (Yasushi Sakata); Resources, T.Y. (Takahisa Yamada), Y.Y., T.H., Y.N., A.N. and M.S.; Supervision, S.H., T.Y. (Takahisa Yamada), Y.Y., S.T., M.Y., Y.N., A.N., M.S. and T.K.; Validation, S.H., H.K. (Hiroyuki Kurakami) and T.Y. (Tomomi Yamada); Writing—original draft, A.S.; Writing—review and editing, S.H. and A.N.; Designing study, OCVC-Heart Failure Investigators; Data acquisition, OCVC-Heart Failure Investigators. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by Roche Diagnostics K.K. and Fuji Film Toyama Chemical Co. Ltd.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Osaka University Hospital on 24 February 2016 (ID: 15471).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Not applicable.

Acknowledgments: The authors thank Nagisa Yoshioka, Kyoko Tatsumi, Satomi Kishimoto, Noriko Murakami, and Sugako Mitsuoka for their excellent assistance with data collection. The OCVC-Heart Failure Investigators: Masahiro Seo, Tetsuya Watanabe, and Takahisa Yamada, Osaka General Medical Center, Osaka, Japan; Takaharu Hayashi and Yoshiharu Higuchi, Osaka Police Hospital, Osaka, Japan;
Masaharu Masuda, Mitsutoshi Asai, and Toshiaki Mano, Kansai Rosai Hospital, Amagasaki, Japan; Hisakazu Fuji, Kobe Eki-saiikai Hospital, Kobe, Japan; Daisaku Masuda, Shunsuke Tamaki, Ryu Shutta, and Shizuya Yamashita, Rinku General Medical Center, Izumisano, Japan; Masami Sairyo and Yusuke Nakagawa, Kawanishi City Hospital, Kawanishi, Japan; Haruhiko Abe, Yasunori Ueda, and Yasushi Matsumura, National Hospital Organization Osaka National Hospital, Osaka, Japan; Kunihiko Nagai, Ikeda Municipal Hospital, Ikeda, Japan; Masamichi Yano, Masami Nishino, and Jun Tanouchi, Osaka Rosai Hospital, Sakai, Japan; Yoh Arita and Nobuyuki Ogasawara, Japan Community Health Care Organization Osaka Hospital, Osaka, Japan; Takamaru Ishizu, Minoru Ichikawa and Yuzuru Takano, Higashiosaka City Medical Center, Higashiosaka, Japan; Eisaí Rin, Kawachi General Hospital, Higashiosaka, Japan; Yukinori Shinoda, Koichi Tachibana and Shiro Hoshia, Yao Municipal Hospital, Yao, Japan; Masahiro Izumi, Kinki Central Hospital, Itami, Japan; Hiroyoshi Yamamoto and Hiroyasu Kato, Japan Community Health Care Organization, Osaka Minato Central Hospital, Osaka, Japan; Kazuhiro Nakatan and Yuji Yasuda, Sumitomo Hospital, Osaka, Japan; Mayu Nishio and Keiji Hirooka, Saiseikai Senri Hospital, Suita, Japan; Takahiro Yoshimura and Yoshinori Yasuoka, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan; Akihiro Tani, Kano General Hospital, Osaka, Japan; Yasushi Okumoto, Kian Hospital, Tanabe, Japan; Yasunaka Makino, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Toshinari Onishi and Katsuomi Iwakura, Sakurabashi Watanabe Hospital, Osaka, Japan; Yoshiyuki Kijima, Japan Community Health Care Organization, Hoshigakou Medical Center, Hirakata, Japan; Takashi Kita and Hideyuki Kanai, Minoh City Hospital, Minoh, Japan; Masashi Fujita, Osaka International Cancer Institute, Osaka, Japan; Koichiro Harada, Saitama Municipal Hospital, Suita, Japan; Masahiro Kumada and Osamu Nakagawa, Toyonaka Municipal Hospital, Toyonaka, Japan; Ryo Araki and Takayuki Yamada, Otouma Hospital, Osaka, Japan; Akihito Nakagawa and Yoshio Yasumura, Amagasaki Chuo Hospital, Amagasaki, Japan; and Taiki Sato, Akihiro Sunaga, Bolranathak Oeun, Hirota Kida, Yohei Sotomi, Tomoharu Dohe, Kei Nakamoto, Katsuki Okada, Fusako Sera, Hidetaka Kioka, Tomohito Ohtani, Toshihiro Takeda, Daisaku Nakatani, Hiroya Mizuno, Shungo Hikoso, and Yasushi Sakata, Osaka University Graduate School of Medicine, Suita, Japan.

Conflicts of Interest: Shungo Hikoso has received remuneration from Daiichi Sankyo Company, and received research funding from Roche Diagnostics, FUJIFILM Toyama Chemical and Actelion Pharmaceuticals. Yoshiharu Higuchi has received remuneration from Daiichi Sankyo Company. Hiroya Mizuno has received endowed department funds from Terumo. Yohei Sotomi has received remuneration from Abbott Vascular Japan and Boston Scientific Japan, received research funding from Abbott Vascular Japan, and endowed department funds from Terumo. Yasushi Sakata has received remuneration from Abbott Vascular Japan and Boston Scientific Japan, received research funding from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo Company and AstraZeneca K.K. and received research funding from Otsuka Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation, Astellas Pharma, Kowa Company, Boehringer Ingelheim Japan, and Biotronik. The other authors (Akihiro Sunaga, Takahisa Yamada, Yoshio Yasumura, Shunsuke Tamaki, Haruhiko Abe, Yusuke Nakagawa, Hisakazu Fuji, Toshiaki Mano, Hiroyuki Kurakami, Tomomi Yamada, Tetsuhisa Kitamura, Taiki Sato, Bolranathak Oeun, Hirota Kida, Katsuki Okada, Shungo Hikoso, and Daisaku Nakatani) have no conflicts of interest to report.

References

1. Narumi, T.; Arimoto, T.; Funayama, A.; Kadowaki, S.; Otaki, Y.; Nishiyama, S.; Takahashi, H.; Shishido, T.; Miyashita, T.; Miyamoto, T.; et al. Prognostic importance of objective nutritional indexes in patients with chronic heart failure. *J. Cardiol.* **2013**, *62*, 307–313. [CrossRef] [PubMed]

2. Sze, S.; Pellicori, P.; Kazmi, S.; Rigby, A.; Cleland, J.G.F.; Wong, K.; Clark, A.L. Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure: A Comparison With Body Mass Index. *JACC Heart Fail.* **2018**, *6*, 476–486. [CrossRef] [PubMed]

3. Rubenstein, L.Z.; Harker, J.O.; Salvà, A.; Guigoz, Y.; Vellas, B. Screening for undernutrition in geriatric practice: Developing the short-form mini-nutritional assessment (MNA-SF). *J. Gerontol. A Biol. Sci. Med. Sci.* **2001**, *56*, M366–M372. [CrossRef] [PubMed]

4. Bouillanne, O.; Morineau, G.; Dupont, C.; Coulombel, I.; Vincent, J.P.; Nicolis, I.; Benazeth, S.; Cynober, L.; Aussel, C. Geriatric Nutritional Risk Index: A new index for evaluating at-risk elderly medical patients. *Am. J. Clin. Nutr.* **2005**, *82*, 777–783. [CrossRef]

5. Ignacio de Ulíbarri, J.; González-Madroño, A.; de Villar, N.G.; González, P.; González, B.; Mancha, A.; Rodríguez, F.; Fernández, G. CONUT: A tool for controlling nutritional status. First validation in a hospital population. *Nutr. Hosp.* **2005**, *20*, 38–45.
6. Alvares-da-Silva, M.R.; Reverbel da Silveira, T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. *Nutrition* **2005**, *21*, 113–117. [CrossRef]

7. Yoshihisa, A.; Kanno, Y.; Watanabe, S.; Yokokawa, T.; Abe, S.; Miyata, M.; Sato, T.; Suzuki, S.; Oikawa, M.; Kobayashi, A.; et al. Impact of nutritional indices on mortality in patients with heart failure. *Open Heart* **2018**, *5*, e000730. [CrossRef]

8. Minamisawa, M.; Miura, T.; Motoki, H.; Ueki, Y.; Nishimura, H.; Shimizu, K.; Shoin, W.; Harada, M.; Mochidome, T.; Senda, K.; et al. Geriatric Nutritional Risk Index Predicts Cardiovascular Events in Patients at Risk for Heart Failure. *Circ. J.* **2018**, *82*, 1614–1622. [CrossRef]

9. Minamisawa, M.; Seidellmann, S.B.; Claggett, B.; Hegde, S.M.; Shah, A.M.; Desai, A.S.; Lewis, E.F.; Shah, S.J.; Sweitzer, N.K.; Fang, J.C.; et al. Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. *JACC Heart Fail.* **2019**, *7*, 664–675. [CrossRef]

10. Kinugasa, Y.; Kato, M.; Sugihara, S.; Hirai, M.; Yamada, K.; Yanagihara, K.; Yamamoto, K. Geriatric nutritional risk index predicts functional dependency and mortality in patients with heart failure with preserved ejection fraction. *Circ. J.* **2013**, *77*, 705–711. [CrossRef]

11. Senni, M.; Paulus, W.J.; Gavazzi, A.; Fraser, A.G.; Diez, J.; Solomon, S.D.; Smiseth, O.A.; Guazzi, M.; Lam, C.S.; Maggioni, A.P.; et al. New strategies for heart failure with preserved ejection fraction: The importance of targeted therapies for heart failure phenotypes. *Eur. Heart J.* **2014**, *35*, 2797–2815. [CrossRef]

12. Nishi, I.; Seo, Y.; Hamada-Harimura, Y.; Yamamoto, M.; Ishizu, T.; Sugano, A.; Sato, K.; Sai, S.; Obara, K.; Suzuki, S.; et al. Geriatric nutritional risk index predicts all-cause deaths in heart failure with preserved ejection fraction. *ESC Heart Fail.* **2019**, *6*, 396–405. [CrossRef]

13. Sullivan, D.H.; Sun, S.; Walls, R.C. Protein-energy undernutrition among elderly hospitalized patients: A prospective study. *JAMA* **1999**, *281*, 2013–2019. [CrossRef]

14. Sunaga, A.; Hikoso, S.; Yamada, T.; Yasmumura, Y.; Uematsu, M.; Tamaki, S.; Abe, H.; Nakagawa, Y.; Higuchi, Y.; Fuji, H.; et al. Prognostic impact of Clinical Frailty Scale in patients with heart failure with preserved ejection fraction. *ESC Heart Fail.* **2021**, *8*, 3316–3326. [CrossRef]

15. Suna, S.; Hikoso, S.; Yamada, T.; Uematsu, Y.; Yasmumura, Y.; Nakagawa, A.; Takeda, T.; Kojima, T.; Kida, H.; Oeun, B.; et al. Study protocol for the PURSUIT-HFpEF study: A Prospective, Multicenter, Observational Study of Patients with Heart Failure with Preserved Ejection Fraction. *BMJ Open* **2020**, *10*, e038294. [CrossRef]

16. Morley, J.E.; Vellas, B.; van Kan, G.A.; Anker, S.D.; Bauer, J.M.; Bernabei, R.; Cesari, M.; Chumlea, W.C.; Doehner, W.; Evans, J.; et al. Frailty consensus: A call to action. *J. Am. Med. Dir. Assoc.* **2013**, *14*, 392–397. [CrossRef]

17. Ismail, N.; Kiprov, D.D.; Hakim, R.M. Plasmapheresis. In *Handbook of Dialysis*, 4th ed.; Daugirdis, J.T., Blake, P.G., Ing, T.S., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007; pp. 276–299.

18. Chen, Y.J.; Sung, S.H.; Cheng, H.M.; Huang, W.M.; Wu, C.L.; Huang, C.J.; Hsu, P.F.; Yeh, J.S.; Guo, C.Y.; Yu, W.C.; et al. Performance of AHEAD Score in an Asian Cohort of Acute Heart Failure With Either Preserved or Reduced Left Ventricular Systolic Function. *J. Am. Heart Assoc.* **2017**, *6*, e004297. [CrossRef]

19. Rich, J.D.; Burns, J.; Freed, B.H.; Maurer, M.S.; Burkhoff, D.; Shah, S.J. Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score Validation: Evaluation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction. *J. Am. Heart Assoc.* **2018**, *7*, e009594. [CrossRef]

20. Chien, S.C.; Lo, C.I.; Lin, C.F.; Sung, K.T.; Tsai, J.P.; Huang, W.H.; Yun, C.H.; Hung, T.C.; Lin, J.L.; Liu, C.Y.; et al. Malnutrition in acute heart failure with preserved ejection fraction: Clinical correlates and prognostic implications. *ESC Heart Fail.* **2019**, *6*, 953–964. [CrossRef]

21. Hirose, S.; Miyazaki, S.; Yatsu, S.; Sato, A.; Ishiwata, S.; Matsumoto, H.; Shitara, J.; Murata, A.; Kato, T.; Suda, S.; et al. Impact of the Geriatric Nutritional Risk Index on In-Hospital Mortality and Length of Hospitalization in Patients with Acute Decompensated Heart Failure with Preserved or Reduced Ejection Fraction. *J. Clin. Med. 2020*, *9*, 1169. [CrossRef]

22. Watanabe, Y.; Horiiuchi, Y.; Nakase, M.; Setoguchi, N.; Ishizawa, T.; Sekiguchi, M.; Nonaka, H.; Nakajima, M.; Asami, M.; Yahagi, K.; et al. Malnutrition, hemodynamics and inflammation in heart failure with reduced, mildly reduced and preserved ejection fraction. *Heart Vessels* **2022**, *37*, 1841–1849. [CrossRef]

23. Evans, W.J.; Morley, J.E.; Argilés, J.; Bales, C.; Baracovs, V.; Guttridge, D.; Jatoi, A.; Kalantar-Zadeh, K.; Lochs, H.; Mantovani, G.; et al. Cachexia: A new definition. *Clin. Nutr.* **2008**, *27*, 793–799. [CrossRef]

24. Pasini, E.; Aquilani, R.; Dioguardi, F.S.; D’Antona, G.; Gheorghiade, M.; Taege, H.; Hypercatabolic Syndrome: Molecular basis and effects of nutritional supplements with amino acids. *Am. J. Cardiol.* **2008**, *101*, 11E–15E. [CrossRef]

25. Kalantar-Zadeh, K.; Anker, S.D.; Horwich, T.B.; Fonarow, G.C. Nutritional and anti-inflammatory interventions in chronic heart failure. *Am. J. Cardiol.* **2008**, *101*, 89E–103E. [CrossRef]

26. Krack, A.; Sharma, R.; Figulla, H.R.; Anker, S.D. The importance of the gastrointestinal system in the pathogenesis of heart failure. *Eur. Heart J.* **2005**, *26*, 2368–2374. [CrossRef]

27. Valentová, M.; von Haehling, S.; Doehner, W.; Murin, J.; Anker, S.D.; Sandek, A. Liver dysfunction and its nutritional implications in heart failure. *Nutrition* **2013**, *29*, 370–378. [CrossRef]

28. Poulia, K.A.; Yannakoulia, M.; Karageorgou, D.; Gamalestou, M.; Panagiotakos, D.B.; Sipsas, N.V.; Zampelas, A. Evaluation of the efficacy of six nutritional screening tools to predict malnutrition in the elderly. *Clin. Nutr.* **2012**, *31*, 378–385. [CrossRef]
29. Saroj, P.; Verma, M.; Jha, K.K.; Pal, M. An overview on immunomodulation. *J. Adv. Sci. Res.* 2012, 3, 7–12.

30. Lin, H.; Zhang, H.; Lin, Z.; Li, X.; Kong, X.; Sun, G. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. *Heart Fail. Rev.* 2016, 21, 549–565. [CrossRef]

31. Bally, M.R.; Blaser Yildirim, P.Z.; Bounoure, L.; Gloy, V.L.; Mueller, B.; Briel, M.; Schuetz, P. Nutritional Support and Outcomes in Malnourished Medical Inpatients: A Systematic Review and Meta-analysis. *JAMA Intern. Med.* 2016, 176, 43–53. [CrossRef]

32. Deutz, N.E.; Matheson, E.M.; Matarese, L.E.; Luo, M.; Baggs, G.E.; Nelson, J.L.; Hegazi, R.A.; Tappenden, K.A.; Ziegler, T.R.; NOURISH Study Group. Readmission and mortality in malnourished, older, hospitalized adults treated with a specialized oral nutritional supplement: A randomized clinical trial. *Clin. Nutr.* 2016, 35, 18–26. [CrossRef] [PubMed]

33. Zhou, H.; Qian, H. Relationship between enteral nutrition and serum levels of inflammatory factors and cardiac function in elderly patients with heart failure. *Clin. Interv. Aging* 2018, 13, 397–401. [CrossRef] [PubMed]

34. Schuetz, P.; Fehr, R.; Baechli, V.; Geiser, M.; Deiss, M.; Gomes, F.; Kutz, A.; Tribolet, P.; Bregenzer, T.; Braun, N.; et al. Individualised nutritional support in medical inpatients at nutritional risk: A randomised clinical trial. *Lancet* 2019, 393, 2312–2321. [CrossRef]

35. Mantovani, G. Preface: Cancer cachexia, from basic research to clinical application: A paradigmatic translational research journey. *Crit. Rev. Oncog.* 2012, 17, 2. [CrossRef]